Johnson & Johnson Archives

News and Trends 26 Jan 2017

Europe’s Largest Biotech Actelion Seals the Deal with J&J for €28B

Actelion will be acquired by J&J for a whopping €27.9B, and its early R&D pipeline will be spun out into a new Switzerland-based outfit. The wait is over folks: Actelion, the largest biotech in Europe and one of the only 9 to make it to the billion-euro club in 2016, has just announced its acquisition by Johnson & Johnson for a […]

January 26, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 13 Jan 2017

UPDATE: J&J and Actelion settle on a price, R&D assets will be spun out

UPDATE (12/01/2017): J&J and Actelion have reportedly settled on a price: $260 (€245) per share, totaling more than $28 (€26) billion. The Swiss biotech’s R&D assets will be spun out into a new company that will remain independent. UPDATE (03/01/2017): The deal has veered towards splitting Actelion into two companies, one for its commercialized portfolio […]

January 13, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Results from 45% of Clinical Trials are kept Secret

A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […]

November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 5 Oct 2016

New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira

New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […]

October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Apr 2016

Biotech Environment in 2016: Reverse Engineering the Ecosystem #BES2016

BIO-Europe Spring 2016 is starting off right away with the plenary opening session. The conference was about partnering, trends and opinion from both Biotechs and Pharma… This was the list of pretty impressive speakers: How are Big Pharma positioning themselves in 2016? J&J clearly wants to open up more to the outside of the organisation, […]

April 4, 2016 - 5 minutesmins - By Philip Hemme

rheumatoid arthritis sirukumab galapagos johnson johnson JJ abbvie

News and Trends 3 Mar 2016

Why is J&J getting rid of Galapagos’ shares, when Everyone else is Buying?

J&J has sold over 2 million of Galapagos‘ shares, which had been inherited from previous acquisitions, reducing its equity in this Belgian Biotech to below 5%. What’s wrong? Back in May, we talked about how J&J and AbbVie could be entering a fight for Galapagos’ filgotinib, a drug for rheumatoid arthritis (RA) that performed well […]

March 3, 2016 - 2 minutesmins - By Denise Neves Gameiro

alzheimers dementia discovery fund takeda weizmann biogen rodin

News and Trends 25 Jan 2016

Also Using PD-L1 Cancer Treatments to Attack Alzheimer’s Disease

What updates have occurred in the Neurodegenerative disease field as of late? New appointments by the Dementia Discovery Fund, which widens its international reach – and new ‘out of the box’ ideas from Israel and South Korea. The Dementia Discovery Fund (DDF), an innovative global investment fund managed by SV Life Sciences and launched in October […]

January 25, 2016 - 3 minutesmins - By Dani Bancroft

embl microbiome janssen eligo enterome jj inra therapeutics crohns

News and Trends 7 Jan 2016

Collaboration is Key to Microbiomics: New Deal with The Janssen Human Microbiome Institute

The Janssen Human Microbiome Institute, the French National Institute for Agricultural Research (INRA) and Johnson & Johnson Innovation AND Takeda are signing up to collaborate with the Paris biotech Enterome to help accelerate Microbiomics research into Crohn’s Disease. The collaboration is based on initial findings by the INRA showing that some commensal (symbiotic) bacteria elicit […]

January 7, 2016 - 3 minutesmins - By Dani Bancroft

women in biotech movers shakers 2015 biobeats

News and Trends 20 Nov 2015

Get to Know the Top 50 Women in the UK’s Biotech Scene

The Movers & Shakers Report 2015 lists 50 of the Top female Bio-Entrepreneurs… here’s a select few I found particularly impressive in the Biotech Industry! Written by Miranda Weston-Smith, the BioBeat15 report is sponsored by Horton Ruston Poole, Johnson & Johnson Innovation, MedImmune and Pfizer to celebrate what women working in bio-business have brought to […]

November 20, 2015 - 5 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

AbbVie abandons Galapagos phase III and stock plummets 39% (and still dropping)

What was AbbVie thinking? Backing out of a $1.4Bn deal to support Belgian biotech Galapagos’ rheumatoid arthritis candidate through its phase III, means NASDAQ stock is plummeting in value since Friday. With plans to work on its own phase II candidate instead, AbbVie is losing out on the potential of filgotinib, which will surely have […]

September 28, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 23 Sep 2015

NovoCure, the Israeli tumor specialist announces NASDAQ €170M IPO

NovoCure, originally from Haifa (Israel) is planning an IPO on NASDAQ with a target of €170M to make from its 12.5M shares on offer. It is hoped this financial injection will further commercialize its FDA-approved tumor treating field (TTField) medical device Optune. NovoCure is a commercial stage oncology biotech specialising in trials for solid-tumor treatments. Founded […]

September 23, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

Promising cure for COPD: Is a breakthrough treatment within reach?

12 biotech unicorns revolutionizing the future of healthcare

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

RNA editing in humans: the race begins with first successful trial

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us